{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.9","value":"3.6"},{"groupId":"OG001","spread":"6.3","value":"4.9"},{"groupId":"OG002","spread":"5.4","value":"4.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"54"}],"units":"Participants"}],"title":"Week 25"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.4","value":"4.7"},{"groupId":"OG001","spread":"6.3","value":"7.6"},{"groupId":"OG002","spread":"5.2","value":"5.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"39"}],"units":"Participants"}],"title":"Week 49"}],"denoms":[{"counts":[{"groupId":"OG000","value":"61"},{"groupId":"OG001","value":"30"},{"groupId":"OG002","value":"91"}],"units":"Participants"}],"description":"The Patient-reported Outcomes Measurement Information System (PROMIS) physical function scale was used to assess physical function of the upper and lower limbs. The scale ranged from 1 defined as 'unable to do' or 'cannot do' to 5 defined as 'without any difficulty' or 'not at all', where higher scores represent better outcomes.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received treatment of Pexidartinib,1000 mg (5 capsules per day) for 2 weeks, then 800 mg (4 capsules per day) for 22 weeks and also received Pexidartinib in Part 2 at their prescribed dose.\n\nPexidartinib: Each capsule contains 200 mg of Pexidartinib for oral administration.","id":"OG000","title":"Pexidartinib Part 1 and Part 2"},{"description":"Participants received treatment of matching placebo (5 capsules per day) for 2 weeks, then matching placebo (4 capsules per day) for 22 weeks in Part 1 and also received Pexidartinib in Part 2 at their prescribed dose.\n\nPlacebo: Placebo capsule matching Pexidartinib capsule for oral administration Pexidartinib: Each capsule contains 200 mg of Pexidartinib for oral administration.","id":"OG001","title":"Placebo Part 1, Pexidartinib Part 2"},{"description":"All participants who received Pexidartinib in Part 1 and Part 2 as well as those who only received Pexidartinib in Part 2.","id":"OG002","title":"All Pexidartinib Treated"}],"paramType":"MEAN","populationDescription":"Physical function was assessed in the ITT population.","reportingStatus":"POSTED","timeFrame":"By Week 49","title":"Mean Change From Baseline in the Patient-reported Outcomes Measurement Information System (PROMIS) Physical Function Score in Participants Receiving Pexidartinib Compared With Those on Placebo by Week 49","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"units on a scale"}